Tomoxifen for metastatic pancreatic adenocarcinoma: A complete response;Rémission complète d'un adénocarcinome du pancréas exocrine métastatique par le tamoxifène

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 10, 2001, Pages 912-913

  Lamy, Régine ^a   Conroy, Thierry ^b   Brunaud, Laurent ^b   Bresler, Laurent ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Metastases; Pancreatic adenocarcinoma; Tamoxifen

Indexed keywords

ANTIESTROGEN; CA 19-9 ANTIGEN; TAMOXIFEN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PANCREATIC NEOPLASMS; REMISSION INDUCTION; TAMOXIFEN;

EID: 0035172508     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. No standard treatment is available for advanced pancreatic cancer
2. Oestrogen receptor protein in malignant and fetal pancreas
3. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas
4. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas. Preliminary study
5. Cell cycle regulation of human pancreatic cancer by tamoxifen
6. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma
7. Unresponsiveness of pancreatic adenocarcinoma to antioestrogen therapy
8. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study
9. Leuprolide and tamoxifen in the treatment of pancreatic cancer. A phase II study
10. Adenocarcinoma of the pancreas - A hormone sensitive tumor? A preliminary report on Nolvadex treatment
11. Antiestrogen therapy in pancreatic carcinoma: A preliminary report
12. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma
13. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater
14. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma
15. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas
16. The use of the tumour marker CA 19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas